| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 10.690 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 10.867 | 99 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 18.660 | 5.233 | 5.043 | 2.659 | 1.263 | 877 | 738 | 759 | 745 | 683 |
| Gross Profit/Loss - EUR | -7.793 | -5.134 | -5.043 | -2.658 | -1.263 | -877 | -738 | -759 | -745 | -683 |
| Net Profit/Loss - EUR | -8.117 | -5.137 | -5.043 | -2.658 | -1.263 | -877 | -738 | -759 | -745 | -683 |
| Employees | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Neogen Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 58.217 | 36.016 | 29.567 | 26.308 | 24.687 | 23.334 | 21.829 | 21.098 | 20.372 | 17.164 |
| Inventories | 3.726 | 3.689 | 3.626 | 3.560 | 3.491 | 3.425 | 3.349 | 3.359 | 3.349 | 3.330 |
| Receivables | 4.882 | 15.135 | 25.733 | 22.099 | 20.697 | 19.629 | 18.255 | 17.609 | 15.968 | 13.054 |
| Cash | 49.608 | 17.192 | 207 | 649 | 500 | 281 | 225 | 130 | 1.055 | 780 |
| Shareholders Funds | 54.004 | 30.502 | 24.943 | 21.827 | 20.141 | 18.882 | 17.725 | 17.022 | 16.225 | 15.451 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 4.213 | 5.514 | 4.624 | 4.481 | 4.546 | 4.452 | 4.103 | 4.077 | 4.147 | 1.713 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4799 - 4799" | |||||||||
| CAEN Financial Year |
4799
|
|||||||||
Comments - Neogen Pharma Srl